CN109077994B - Small molecular hydrogel-nanoparticle composite drug carrier and application thereof in skin/mucosa drug delivery system - Google Patents
Small molecular hydrogel-nanoparticle composite drug carrier and application thereof in skin/mucosa drug delivery system Download PDFInfo
- Publication number
- CN109077994B CN109077994B CN201811025663.3A CN201811025663A CN109077994B CN 109077994 B CN109077994 B CN 109077994B CN 201811025663 A CN201811025663 A CN 201811025663A CN 109077994 B CN109077994 B CN 109077994B
- Authority
- CN
- China
- Prior art keywords
- carrier
- drug
- hydrogel
- skin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a small-molecule hydrogel-nanoparticle composite drug carrier and application thereof in a skin/mucosa drug delivery system. The micromolecular hydrogel-nanoparticle composite carrier is used for skin/mucosa administration, the permeability of the skin/mucosa and focus parts of the medicine can be obviously improved by modifying the surface of the nanoparticle with the cell-penetrating peptide, and the micromolecular hydrogel solves the problem that the medicine is easy to lose when being administered in a solution dosage form.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a small-molecular hydrogel-nanoparticle composite drug carrier and application thereof in a skin/mucosa drug delivery system.
Background
Skin/mucosal administration refers to the application of drugs through the skin or mucous membranes of various cavities (such as oral cavity, nasal cavity, lung, etc.). The administration mode can avoid the damage of the gastrointestinal tract to the medicine and the irritation of the medicine to the gastrointestinal tract, and compared with intravenous administration, the administration mode can directly administer the medicine at the skin/mucous membrane part of the focus, so that the medicine can quickly reach the focus part, the medicine concentration of the focus part is obviously improved, and the distribution of non-target tissues is reduced. Thus a simple, fast and patient-friendly route of administration. But the manner of dermal/mucosal administration also presents challenges: the drugs are absorbed through the skin or the surface of the mucous membrane and pass through the hydrophobic area of the cell lipid membrane, the hydrophobic structure has a limiting effect on the penetration of the drugs, and the outermost layer of the skin is a compact stratum corneum, so that the strong hydrophobic structure creates a larger barrier for the penetration of the drugs.
The passive diffusion of the drug penetrating through the biological membrane has close relation with the lipid solubility of the drug, the lipid solubility of the drug is generally measured by an oil/water partition coefficient, and the lipid solubility is large if the oil/water partition coefficient is large, so that the transmembrane transport of the drug is facilitated. The passive absorption rate of the medicine is related to the diffusion coefficient of the medicine, and the medicine with large molecular weight has large diffusion resistance and slow diffusion rate and is difficult to penetrate through skin, the surface biomembrane of the pulmonary alveoli, nasal mucosa and the like. Drugs suitable for transdermal/mucosal administration should have a large oil-water partition coefficient, and should not exceed a molecular weight of 1000, and thus are limited in kind.
The variety of transdermally delivered drugs can be expanded by increasing the drug permeability by some means. At present, there are many methods for improving the transdermal efficiency of drugs, which are mainly divided into an active type and a passive type, and the passive type method is a method using a chemical penetration enhancer, a biological peptide and a pharmaceutical preparation carrier, such as: lipid nanoparticles (liposomes), metal nanoparticles, polymer nanoparticles, and the like; active methods are those that disturb or disrupt the skin's barrier by physical means, such as microneedles, microwaves, iontophoresis, electroporation, sonophoresis, magnetic introduction, laser, etc.
However, the method of improving drug permeability by using drug preparation carriers such as lipid nanoparticles (liposomes), metal nanoparticles, polymer nanoparticles, and the like generally has the problems of short retention time of the preparation at the skin/mucosa administration site and frequent administration.
Disclosure of Invention
The invention aims to provide a small-molecular hydrogel-nanoparticle composite drug carrier and application thereof in a skin/mucosa drug delivery system.
The small molecular hydrogel-nanoparticle composite drug carrier comprises drug-loaded nanoparticles and small molecular hydrogel, wherein the drug-loaded nanoparticles are dispersed in the small molecular hydrogel; cell-penetrating peptide is modified on the surface of the drug-loaded nanoparticles.
Further, the drug-loaded nanoparticles are selected from liposomes, transfersomes, solid lipid nanoparticles, nanoemulsions, microemulsions, vesicles, dendrimers, micelles, polymeric nanoparticles or inorganic nanoparticles, such as carbon nanotubes, gold nanoparticles, quantum dots and the like.
Further, the drug loaded by the drug-loaded nanoparticles is selected from small molecule drugs, such as adriamycin, paclitaxel, hamporfin, ereoxib, vemurafenib and the like; or biological macromolecular drugs such as polypeptides, proteins, enzymes, hormones, vaccines, cell growth factors, monoclonal antibodies, glycans, and nucleic acids.
Further, the cell-penetrating peptide is selected from td (acssspskhcg), tat (grkkrrqrrrpq), T2(LVGVFH), 11R (rrrrrrrrrrrrrrr), R8H3(RRRRRRRRHHH), and the like.
Further, the small molecule hydrogel is formed by ordered arrangement and spontaneous aggregation of a gelator with the molecular weight of less than 2000 under the action of non-covalent bonds. Self-assembly of the system to form small molecule hydrogels can be initiated by changing pH, temperature, electric field, magnetic field, ionic strength, addition of chemicals, introduction of light or enzymes.
The application of the small molecular hydrogel-nanoparticle composite drug carrier in a skin/mucosa drug delivery system.
A small molecular hydrogel-transfersome composite drug carrier is composed of a drug-loaded transfersome and a small molecular hydrogel, wherein the drug-loaded transfersome is dispersed in the small molecular hydrogel;
the drug-loaded carrier is prepared from phospholipid, sodium deoxycholate and tween, and loads paclitaxel or coumarin 6, the surface of the drug-loaded carrier is modified with cell-penetrating peptide which is stearic acid modified octa-arginine tri-histidine (Stearylated-octaarginin-trihistine, Ste-RRRRRRRRHHH, Ste-R8H 3);
the micromolecular hydrogel is prepared from gel precursors including fluorenylmethyloxycarbonyl-phenylalanine and phenylalanine-dihydroxyphenylalanine.
The preparation method of the small molecular hydrogel-carrier composite drug carrier comprises the following steps:
step 1, preparing a carrier by a thin film dispersion method: dissolving soybean lecithin, a surfactant and a fat-soluble drug in an organic solvent, removing the organic solvent by vacuum rotary evaporation, adding double distilled water for hydration, and filtering after ultrasonic treatment to obtain a carrier;
step 3, preparing the small molecular hydrogel-carrier composite drug carrier: dissolving the gel precursor in distilled water, adjusting pH to 7.4, adding transfersome, adding enzyme solution, mixing, and reacting in 37 deg.C incubator for 4 h.
A transfersome: also known as elastoliposomes (flexible nanoliposomes), in 1992 the Cevc group described the transfersome for the first time as a liposome for transdermal administration, which is more deformable and elastic than conventional liposomes. The carrier is an artificial carrier composed of phospholipids and surfactants, also known as Edge Activators (EA), which determine the morphology of the carrier. Transdermal mechanism of the transfersome: the carrier can self-polymerize, can transmit the drug to restore the original shape after penetrating the skin, has better elasticity than the traditional liposome, and the high deformability ensures that the carrier can penetrate through the pores with the grain diameter 5-10 times smaller than the self grain diameter through deformation, thereby being a new transdermal drug transmission carrier. The mechanism for enhancing transdermal drug delivery is not clear at this stage, and two mechanisms have been reported: 1) the transfersome is used as a drug carrier and can keep an intact shape after penetrating through the skin; 2) the carrier acts as a permeation enhancer, interfering with the highly ordered intercellular lipids of the stratum corneum, thereby facilitating the penetration of the drug through and across the stratum corneum.
The small molecule hydrogel is a three-dimensional network structure formed by self-assembly of small molecules to form supramolecular chains and then cross-linking and winding of each chain to wrap water molecules in the middle. Methods for initiating self-assembly to form hydrogels can be broadly divided into two categories: one is to start self-assembly by adjusting the system environment, such as changing pH, temperature, electric field, magnetic field, ionic strength, chemical substances, etc.; another is the stimulation of precursors that are not capable of self-assembly to form gel elements that are capable of self-assembly, such as photo-or enzymatic catalysis. The small molecular hydrogel can be used as a new biological material to be applied to tissue engineering, cell culture matrixes, drug delivery and the like. Moreover, the three-dimensional network structure formed by self-assembly can wrap water molecules, other bioactive molecules (nutrients and proteins) and medicines, and can be used as a medicine sustained and controlled release carrier.
Cell Penetrating Peptides (CPPs) are short peptides that have the ability to penetrate the Cell membrane. In 1988, the HIV transactivator tat (GRKKRRQRRPQ) of the transcription protein is firstly discovered to have the capability of passing through a plasma membrane and entering cells. Since 1994 first delivered exogenous short peptides using cell-penetrating peptides as carriers, various cell-penetrating peptides have emerged, which are capable of successfully delivering proteins, nucleic acids, small molecule drugs, antibodies, nanocarriers, and the like. Santan Patra and the like connect oligoarginine to cholesterol to synthesize the membrane-penetrating peptide modified liposome, and in vivo and in vitro experiments show that the modification of the membrane-penetrating peptide can obviously improve the skin permeability of curcumin, thereby proving that the membrane-penetrating peptide plays an important role in skin permeation and transdermal release.
The micromolecular hydrogel-nanoparticle composite carrier is used for skin/mucosa administration, the permeability of the skin/mucosa and focus parts of the medicine can be obviously improved by modifying the surface of the nanoparticle with the cell-penetrating peptide, and the micromolecular hydrogel solves the problem that the medicine is easy to lose when being administered in a solution dosage form.
Drawings
FIG. 1 is a schematic diagram of the preparation of a small molecule hydrogel-carrier composite drug carrier in example 1;
FIG. 2 is a graph showing the distribution of the particle size of the cell-penetrating peptide-modified carrier in example 1;
FIG. 3 is a comparison of the in vitro cumulative skin penetration of the drug of the transfersomes, cell-penetrating peptide modified transfersomes and liposomes of example 1;
FIG. 4 is SEM image of lyophilized sample of the small molecule hydrogel-carrier composite drug carrier in example 1, wherein the scale in FIG. a is 100 μm and the scale in FIG. b is 1 μm;
FIG. 5 shows the in vitro cumulative transdermal rate of the small molecule hydrogel-carrier composite drug carrier of example 1.
Detailed Description
Example 1
Preparation of blank transfersomes: transfersome was prepared by thin film dispersion method, phospholipid (SPC), sodium deoxycholate and surface active ingredient (EA) were dissolved in chloroform according to the ratio of table 1: methanol 2: 1 at 40 deg.C, removing the organic solvent by vacuum rotary evaporation to form lipid film on the bottle wall, and vacuum drying overnight to remove residual organic solvent. Addition of ddH2O hydration for 10min, dispersing the lipid suspension by using a probe type cell ultrasonicator to perform ice bath ultrasound for 5min, and passing the ultrasound liposome suspension through a 0.22 mu m cellulose ester film to obtain a carrier (Ts) with uniform particle size. Conventional liposomes (Ls) were also prepared as controls.
Preparing a drug-loaded carrier: the preparation of the carrier carrying Paclitaxel (PTX) or coumarin 6(Cou6) only needs to dissolve PTX (or Cou6) and lipid components in an organic solvent and prepare the carrier by the method, wherein the loading amount of PTX is 3.3 percent of the total mass of the lipid components, and the loading amount of coumarin 6 is 0.2 percent of the total mass of the lipid components. And preparing traditional medicine-carrying liposome (Ls).
TABLE 1 composition of the different liposomes
Preparation of cell-penetrating peptide modified transfersome: adding cell-penetrating peptide solution with lipid content of 2.5 mol% into the obtained transfersome, and incubating at 4 deg.C for 40 min;
the particle size of the paclitaxel-loaded cell-penetrating peptide-modified carrier is measured by a dynamic light scattering method, and the result is shown in fig. 2, which shows that the particle size distribution is about 75nm, the particle size is normally distributed, and the distribution is uniform.
In vitro transdermal test: the transdermal capacity of Cou6-CTs was examined using a transdermal diffusion apparatus, male nude mice at 6-7 weeks were sacrificed and then excised from the abdominal skin, and the subcutaneous tissue was removed with scissors and then the adherent adipose layer and connective tissue were removed with isopropanol, taking care not to damage the skin during this procedure, and finally washed with 0.9% NaCl for future use. Setting the stirring speed at 500rpm, fixing the treated skin on a Franz diffusion cell, wherein the stratum corneum of the skin faces to a dosing cell, the inner layer of the skin is contacted with a buffer solution in a sample receiving cell, and the buffer solution is prepared from ethanol: PBS 1: 3, and is used after ultrasonic bubble removal treatment. 300 μ L of different liposome samples were uniformly added to the dosing reservoir to give a dosing area of 3.14cm2800 μ L of sample was taken from the sample receiving well at 0.5, 1, 2, 4, 6, 8, 12h, and the same volume of buffer was replenished after each sampleAnd (6) flushing liquid. The cumulative drug permeability was calculated as follows:
a is the dose, V is the volume of the receiving solution, Cn is the concentration of the sample sampled at the nth time, Ci is the concentration of the sample in the receiving solution at the ith time, and Vi is the sampling volume.
The cumulative release rate calculation is shown in FIG. 3: transdermal results show that the transfersomes (Ts, CTs) have good transdermal effect compared with the traditional liposomes (Ls), and the transdermal efficiency of the transfersomes is obviously improved after the CPP is added, and compared with the traditional liposomes, the transdermal efficiency of the transfersomes CTs in the experimental design is improved by nearly 4 times.
Preparing a small molecular hydrogel-carrier composite carrier: taking a certain amount of 10mM fluorenylmethoxycarbonyl-phenylalanine (Fmoc-F) and 20mM phenylalanine-dihydroxyphenylalanine (F-F-DOPA) as gel precursors, fully dissolving the gel precursors in distilled water, then uniformly mixing the gel precursors with 250 mu L of transfersome (CTs) after the pH is about 7.4, then adding 200 mu L of WQ9-2 enzyme solution (1mg/mL, strain Bacillus WQ9-2(CN102021125A), wherein the produced protein WQ9-2 has the performance of catalyzing and synthesizing hydrogel factors), uniformly mixing, placing in a 37 ℃ incubator, and reacting for 4 hours.
Fig. 4 is an SEM image of a small molecule hydrogel-carrier composite carrier lyophilized sample, wherein the SEM after vacuum freeze-drying of the sample can be used for observing a three-dimensional network structure formed after the gelator is wound and aggregated by a self-assembly manner. From figure a it can be seen that the three-dimensional skeleton of the hydrogel is cross-linked by a dendritic structure to form a porous structure. The size of the skeleton is about 10-30 μm, the porous scaffold structure provides skeleton support for the gel on one hand and can be loaded with drugs on the other hand, and the partial enlargement of the figure b (namely the figure b) can see that the transfersome is loaded in the gel gap structure and the size of the transfersome is about 100 nm.
Small molecule hydrogel-transfersome in vitro transdermal test: the operation method and the in vitro transdermal test of the carrier, the calculation result of the cumulative release rate is shown in figure 5: the 12h transdermal results for the small molecule hydrogel-transfersome were about 12%, indicating that the small molecule hydrogel as a depot may slow the transdermal speed of the transfersome.
Claims (1)
1. A small molecule hydrogel-transfersome composite drug carrier is characterized in that: the drug-loaded carrier is dispersed in the micromolecular hydrogel;
the drug-loaded carrier is prepared from phospholipid, sodium deoxycholate and tween, and is loaded with paclitaxel, and cell-penetrating peptide is modified on the surface of the drug-loaded carrier and is stearic acid-modified octa-arginine tri-histidine polymer; the micromolecular hydrogel is prepared from gel precursors including fluorenylmethyloxycarbonyl-phenylalanine and phenylalanine-dihydroxyphenylalanine;
the preparation method of the small molecular hydrogel-carrier composite drug carrier comprises the following steps:
step 1, preparing a carrier by a thin film dispersion method: dissolving phospholipid, sodium deoxycholate, tween and paclitaxel in an organic solvent, removing the organic solvent by vacuum rotary evaporation, adding double distilled water for hydration, performing ultrasonic treatment, and filtering to obtain a carrier, wherein the dosage ratio of the phospholipid, the sodium deoxycholate and the tween is 80: 10: 10;
step 2, modifying the surface of the drug-loaded carrier with cell-penetrating peptides: incubating the carrier and cell-penetrating peptide solution at 4 deg.C for 40 min;
step 3, preparing the small molecular hydrogel-carrier composite drug carrier: dissolving gel precursors including fluorenylmethyloxycarbonyl-phenylalanine and phenylalanine-dihydroxyphenylalanine in distilled water, adjusting the pH to 7.4, adding a carrier, adding WQ9-2 enzyme solution, mixing uniformly, and placing in an incubator at 37 ℃ for reaction for 4 hours to obtain the product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811025663.3A CN109077994B (en) | 2018-09-04 | 2018-09-04 | Small molecular hydrogel-nanoparticle composite drug carrier and application thereof in skin/mucosa drug delivery system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811025663.3A CN109077994B (en) | 2018-09-04 | 2018-09-04 | Small molecular hydrogel-nanoparticle composite drug carrier and application thereof in skin/mucosa drug delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109077994A CN109077994A (en) | 2018-12-25 |
| CN109077994B true CN109077994B (en) | 2021-11-30 |
Family
ID=64840858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811025663.3A Active CN109077994B (en) | 2018-09-04 | 2018-09-04 | Small molecular hydrogel-nanoparticle composite drug carrier and application thereof in skin/mucosa drug delivery system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109077994B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109998994B (en) * | 2018-02-13 | 2021-12-07 | 四川大学 | Flexible liposome containing medicine and preparation method thereof |
| CN111686075B (en) * | 2019-03-15 | 2021-09-17 | 四川大学 | In-situ hydrogel composition taking nano-micelle as cross-linking agent and application thereof |
| CN111568855B (en) * | 2020-06-08 | 2022-02-08 | 山东大学 | Preparation method of injectable hydrogel and application of injectable hydrogel in postoperative tumor treatment |
| CN113559054A (en) * | 2021-05-14 | 2021-10-29 | 南京工业大学 | Active oxygen scavenging/responding allosteric self-assembly hydrogel and application thereof |
| CN113908138A (en) * | 2021-09-08 | 2022-01-11 | 四川大学华西医院 | Glioma antibody pharmaceutical composition and preparation method thereof |
| CN114107397A (en) * | 2021-11-19 | 2022-03-01 | 深圳市大鳄生物科技股份有限公司 | Delivery system, complex and drug for delivering negatively charged nucleic acids |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711874A (en) * | 2008-10-08 | 2010-05-26 | 广州暨南大学医药生物技术研究开发中心 | Application of cell penetrating peptide Tat-mediated growth factor in transdermal transfer |
| CN102091036A (en) * | 2011-01-10 | 2011-06-15 | 中国药科大学 | Compound liposome containing anti-tumor drugs and preparation method and application thereof |
| CN102174078A (en) * | 2011-01-10 | 2011-09-07 | 中国药科大学 | Application of tumor cell membrane selectively penetrating peptide |
| CN102406609A (en) * | 2011-12-01 | 2012-04-11 | 天津医科大学口腔医院 | Lidocaine hydrochloride polymeric liposome for topical anesthesia and preparation method |
| CN102743338A (en) * | 2012-05-09 | 2012-10-24 | 中国药科大学 | Oral composite nano-carrier based on cell-permeable peptide, preparation method and use thereof |
| CN103655455A (en) * | 2012-09-11 | 2014-03-26 | 上海交通大学医学院附属第九人民医院 | Nanoscale carrier loading 5-fluorouracil gel and preparation method thereof |
| CN105310983A (en) * | 2014-08-03 | 2016-02-10 | 孙仁 | Rupturable PEG modified adriamycin liposome preparation method |
| CN106177986A (en) * | 2016-08-16 | 2016-12-07 | 国家纳米科学中心 | A kind of lipopolymer medicine-carried nano particles and its preparation method and application |
| CN107088184A (en) * | 2017-04-21 | 2017-08-25 | 南京工业大学 | Orient Enzymatic reac tion system and its application in micro-molecular hydrogel is prepared |
| KR101813560B1 (en) * | 2016-06-24 | 2018-01-31 | 주식회사 바이오에프디엔씨 | Topical formulation with Skin Physiological Activity Composed of Cell Permeable Growth Factors |
| CN107815470A (en) * | 2017-10-11 | 2018-03-20 | 江苏大学 | A kind of preparation method of the compound gene activation support of liposome/gel |
| CN107998070A (en) * | 2017-12-12 | 2018-05-08 | 南京中医药大学 | A kind of composite phospholipid carrier and its application in percutaneous drug administration preparation is prepared |
-
2018
- 2018-09-04 CN CN201811025663.3A patent/CN109077994B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711874A (en) * | 2008-10-08 | 2010-05-26 | 广州暨南大学医药生物技术研究开发中心 | Application of cell penetrating peptide Tat-mediated growth factor in transdermal transfer |
| CN102091036A (en) * | 2011-01-10 | 2011-06-15 | 中国药科大学 | Compound liposome containing anti-tumor drugs and preparation method and application thereof |
| CN102174078A (en) * | 2011-01-10 | 2011-09-07 | 中国药科大学 | Application of tumor cell membrane selectively penetrating peptide |
| CN102406609A (en) * | 2011-12-01 | 2012-04-11 | 天津医科大学口腔医院 | Lidocaine hydrochloride polymeric liposome for topical anesthesia and preparation method |
| CN102743338A (en) * | 2012-05-09 | 2012-10-24 | 中国药科大学 | Oral composite nano-carrier based on cell-permeable peptide, preparation method and use thereof |
| CN103655455A (en) * | 2012-09-11 | 2014-03-26 | 上海交通大学医学院附属第九人民医院 | Nanoscale carrier loading 5-fluorouracil gel and preparation method thereof |
| CN105310983A (en) * | 2014-08-03 | 2016-02-10 | 孙仁 | Rupturable PEG modified adriamycin liposome preparation method |
| KR101813560B1 (en) * | 2016-06-24 | 2018-01-31 | 주식회사 바이오에프디엔씨 | Topical formulation with Skin Physiological Activity Composed of Cell Permeable Growth Factors |
| CN106177986A (en) * | 2016-08-16 | 2016-12-07 | 国家纳米科学中心 | A kind of lipopolymer medicine-carried nano particles and its preparation method and application |
| CN107088184A (en) * | 2017-04-21 | 2017-08-25 | 南京工业大学 | Orient Enzymatic reac tion system and its application in micro-molecular hydrogel is prepared |
| CN107815470A (en) * | 2017-10-11 | 2018-03-20 | 江苏大学 | A kind of preparation method of the compound gene activation support of liposome/gel |
| CN107998070A (en) * | 2017-12-12 | 2018-05-08 | 南京中医药大学 | A kind of composite phospholipid carrier and its application in percutaneous drug administration preparation is prepared |
Non-Patent Citations (5)
| Title |
|---|
| Enhanced Transdermal Drug Delivery by Transfersome-Embedded Oligopeptide Hydrogel for Topical Chemotherapy of Melanoma;Tianyue Jiang等;《ACS Nano》;20180905;第12卷;第9693-9701页 * |
| Enzymatic formation of a novel cell-adhesive hydrogel based on small peptides with a laterally grafted L-3,4-dihydroxyphenylalanine group;J. X. Xu等;《Nanoscale》;20131106;第6卷;第1277-1280页 * |
| Gel–Liposome-Mediated Co-Delivery of Anticancer Membrane-Associated Proteins and Small-Molecule Drugs for Enhanced Therapeutic Efficacy;Tianyue Jiang等;《ADVANCED FUNCTIONAL MATERIALS》;20141231;第24卷(第16期);摘要，第2296页右栏第1段至2297页左栏第1段，第2302页右栏第3段 * |
| 姜黄素脂质体和脂质体凝胶的制备及其经皮给药研究;吴青青;《万方学位论文》;20130426;全文 * |
| 紫杉醇纳米脂质体凝胶剂的制备及体外透皮研究;杨秀丽等;《中国现代应用药学》;20150228;第32卷(第2期);摘要，第2.4小节，第157页左栏第11-14行，第3小节结论部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109077994A (en) | 2018-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109077994B (en) | Small molecular hydrogel-nanoparticle composite drug carrier and application thereof in skin/mucosa drug delivery system | |
| Dymek et al. | Liposomes as biocompatible and smart delivery systems–The current state | |
| Chaurasiya et al. | Transfersomes: a novel technique for transdermal drug delivery | |
| Pawar | Transfersome: A novel technique which improves transdermal permeability | |
| US8715736B2 (en) | Nanoparticle formulations for skin delivery | |
| Chen | Current and future technological advances in transdermal gene delivery | |
| EP2288336B1 (en) | Nanostructures suitable for sequestering cholesterol | |
| YADAV | Drug Delivery Reviews | |
| Kumar | Transferosome: A recent approach for transdermal drug delivery | |
| CN111569082B (en) | Oral delivery system for protein-loaded polypeptide drug exosomes | |
| Kuznetsova et al. | Enhancement of the transdermal delivery of nonsteroidal anti-inflammatory drugs using liposomes containing cationic surfactants | |
| Costa et al. | One-step microfluidics production of enzyme-loaded liposomes for the treatment of inflammatory diseases | |
| Aldawsari et al. | Progress in topical siRNA delivery approaches for skin disorders | |
| Tripathy et al. | Transdermal delivery of kidney-targeting nanoparticles using dissolvable microneedles | |
| CN114432230B (en) | Microneedle for treating psoriasis by percutaneous delivery liposome and preparation method thereof | |
| Yuan et al. | Nanocarriers for promoting skin delivery of therapeutic agents | |
| US9919002B2 (en) | Methods and constructs for compound delivery | |
| Luo et al. | A nanoscale polymeric penetration enhancer based on polylysine for topical delivery of proteins and peptides | |
| Ye et al. | Functionalized multiwalled carbon nanotube-ethosomes for transdermal delivery of ketoprofen: Ex vivo and in vivo evaluation | |
| Cevc | Transfersomes: Innovative transdermal drug carriers | |
| Jiang et al. | Binary ethosomes-based transdermal patches assisted by metal microneedles significantly improve the bioavailability of carvedilol | |
| Nayak et al. | Nanovesicular systems in drug delivery | |
| CN102188379A (en) | Preparation method of drug-carrying liposome | |
| Jain et al. | Elastic liposomes bearing meloxicam-β-cyclodextrin for transdermal delivery | |
| JPWO2005021012A1 (en) | Gemcitabine encapsulated drug carrier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |